Ann arbor stage II grade 3 non-contiguous follicular lymphoma

Clinical trials for Ann arbor stage II grade 3 non-contiguous follicular lymphoma explained in plain language.

Never miss a new study

Get alerted when new Ann arbor stage II grade 3 non-contiguous follicular lymphoma trials appear

Sign up with your email to follow new studies for Ann arbor stage II grade 3 non-contiguous follicular lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New cocktail of cancer drugs shows promise in early lymphoma trial

Disease control Ongoing

This early-phase trial is testing a combination of three drugs—rituximab, lenalidomide, and ibrutinib—in people with untreated follicular lymphoma. The goal is to find the safest dose and see how well patients tolerate the mix. The study includes 33 participants with stage II to …

Matched conditions: ANN ARBOR STAGE II GRADE 3 NON-CONTIGUOUS FOLLICULAR LYMPHOMA

Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jun 27, 2026 14:03 UTC

Ann arbor stage II grade 3 non-contiguous follicular lymphoma

Get alerted when new Ann arbor stage II grade 3 non-contiguous follicular lymphoma trials appear

New cocktail of cancer drugs shows promise in early lymphoma trial